GNH USA

Europe — EMA

Granisetron Orchid Europe

Granisetron Orchid Europe is an oral 5‑HT3 antagonist used to prevent chemotherapy‑ and postoperative‑induced nausea and vomiting in the EU.

Granisetron Hydrochloride

Request sourcing

1
Pack/s

What is Granisetron Hydrochloride?

Granisetron Orchid Europe is a prescription oral medication containing granisetron hydrochloride, a selective 5‑HT3 receptor antagonist. It is marketed in the European Union and is used as an antiemetic to help prevent nausea and vomiting associated with chemotherapy and postoperative settings. The product is supplied without a specified strength or dosage form in this description. It belongs to the therapeutic class of antiemetics and is available only with a prescription.

What is Granisetron Hydrochloride used for?

Granisetron Orchid Europe is indicated for the prevention of nausea and vomiting in specific clinical situations.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of postoperative nausea and vomiting (PONV). - Use as part of a multimodal antiemetic regimen for highly emetogenic chemotherapy. - May be considered when other 5‑HT3 antagonists are not suitable.

What are the side effects of Granisetron Hydrochloride?

The safety profile of granisetron includes both frequently observed and rare adverse events.

Common: - Headache. - Constipation. - Dizziness. - Fatigue. - Mild diarrhea. - Transient visual disturbances.

Serious: - Severe allergic reaction (anaphylaxis). - QT interval prolongation leading to cardiac arrhythmia. - Severe constipation causing intestinal obstruction. - Serotonin syndrome (rare). - Severe hypotension.

What precautions apply to Granisetron Hydrochloride?

Before prescribing Granisetron Orchid Europe, clinicians should evaluate several precautionary factors.

- Assess cardiac history, especially risk of QT prolongation. - Review concomitant medications that affect cardiac conduction. - Use caution in patients with hepatic impairment. - Monitor for signs of hypersensitivity during initial doses. - Consider pregnancy and breastfeeding status; safety data are limited.

What does Granisetron Hydrochloride interact with?

Granisetron may interact with other drugs, requiring attention to avoid or adjust therapy.

Avoid: - Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics). - Combination with other 5‑HT3 antagonists. - Use with potent CYP3A4 inhibitors if metabolic pathways are relevant.

Use with caution: - Co‑administration with drugs that lower the seizure threshold. - Concomitant use of opioids that can increase constipation. - Use with drugs that may cause electrolyte disturbances (e.g., diuretics) that could exacerbate QT prolongation.

Frequently asked questions

What is Granisetron Orchid Europe and how does it work?+
Granisetron Orchid Europe is a prescription oral drug that contains granisetron hydrochloride, a selective antagonist of serotonin 5‑HT3 receptors. By blocking these receptors in the central nervous system and gastrointestinal tract, it interferes with the signaling pathway that triggers nausea and vomiting.
For which types of chemotherapy is Granisetron Orchid Europe recommended?+
It is commonly used for chemotherapy regimens that are moderately to highly emetogenic, including agents such as cisplatin, carboplatin, cyclophosphamide, and anthracycline‑based protocols.
How is Granisetron Orchid Europe administered and what is the typical dosing schedule?+
Granisetron Orchid Europe is taken by mouth. The exact dose and schedule depend on the clinical context and are determined by the prescribing clinician, often administered before chemotherapy or surgery and may be continued for several days afterward.
Can Granisetron Orchid Europe be used in patients with a history of cardiac arrhythmias?+
Caution is advised. Because granisetron can prolong the QT interval, clinicians should evaluate the patient’s cardiac history and consider ECG monitoring, especially if other QT‑prolonging drugs are used.
What are the most common side effects reported with Granisetron Orchid Europe?+
The most frequently reported adverse effects include headache, constipation, dizziness, fatigue, mild diarrhea, and transient visual disturbances.
Are there any serious adverse reactions that require immediate medical attention?+
Yes. Serious reactions such as severe allergic response (anaphylaxis), significant QT prolongation leading to arrhythmia, severe constipation with obstruction, serotonin syndrome, or sudden hypotension should prompt urgent medical evaluation.
Which medications should be avoided while taking Granisetron Orchid Europe?+
Drugs that also prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics) and other 5‑HT3 antagonists should be avoided to reduce the risk of additive effects.
How should Granisetron Orchid Europe be adjusted for patients with liver impairment?+
Granisetron is primarily excreted unchanged, but clinicians may consider dose adjustment or increased monitoring in patients with moderate to severe hepatic impairment.
Is Granisetron Orchid Europe safe to use during pregnancy or breastfeeding?+
Safety data in pregnancy and lactation are limited, so the drug should be used only if the potential benefit justifies the potential risk to the fetus or infant.
How does Granisetron Orchid Europe compare to other 5‑HT3 antagonists?+
Granisetron has a similar efficacy profile to other agents in its class, such as ondansetron and palonosetron, but may differ in half‑life, dosing frequency, and specific drug‑interaction potentials.
Can Granisetron Orchid Europe be combined with other antiemetic agents?+
Yes, it is often used as part of a multimodal regimen that may include dexamethasone, NK1‑receptor antagonists, or antihistamines to enhance anti‑nausea control.
What monitoring is recommended for patients on Granisetron Orchid Europe?+
Baseline and periodic ECG monitoring is advisable for patients at risk of QT prolongation, along with observation for signs of hypersensitivity and assessment of bowel function.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Granisetron Hydrochloride
Route
Oral
Manufacturer
Orchid Europe Limited
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU